Coronary heart disease and genetic variants with low phospholipase A+ADw-inf+AD4-2+ADw-/inf+AD4-Activity

New England Journal of Medicine

Volumn 372, Issue 3, 2015, Pages 295-296

  Polfus, Linda M ^a   Gibbs, Richard A ^b   Boerwinkle, Eric ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; PHOSPHOLIPASE A2;

ADULT; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME ACTIVITY; EXOME; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLA2G7 GENE; RISK ASSESSMENT; SEQUENCE ANALYSIS; AFRICAN AMERICAN; AGED; CAUCASIAN; CORONARY DISEASE; ETHNOLOGY; GENETICS; HETEROZYGOTE; METABOLISM; MUTATION; RISK FACTOR;

AFRICAN AMERICANS; AGED; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXOME; FEMALE; GENETIC VARIATION; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHOLIPASES A2; RISK FACTORS;

EID: 84920972850     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1409673     Document Type: Letter

References (5)

1. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
2. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebocontrolled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19.
3. Münzel T, Gori T. Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability. Eur Heart J 2009;30:2829-31.
4. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44.
5. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11.